Yan Liu1, Zhi-Zhen Huang2, Li Min3, Zhi-Feng Li4, Kui Chen5. 1. Department of Respiratory and Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 2. Department of Stomatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 3. Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 4. Department of Orthopedics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China. 5. Department of Emergency Medicine, Affiliated Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei, China. ckck_kui5@126.com.
Abstract
OBJECTIVE: To examine the effect of the BRD4 inhibitor JQ1 on mice with chronic obstructive pulmonary disease (COPD) via NF-κB. METHODS: COPD models constructed by exposure to cigarette smoke and intratracheal instillation of lipopolysaccharides (LPS) in mice were treated with JQ1 (15, 25 or 50 mg/kg). HE staining was performed to observe histopathological changes in the lung tissues. Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of IL-10, IFN-γ, IL-17, IL-1β, IL-6, TNF-α, MMP-2, MMP-9, MDA, SOD, T-AOC and HO-1, and gelatin zymography assays were used to examine MMP-2 and MMP-9 activity. A TransAMTM NF-κB p65 detection kit was used to test NF-κB p65/DNA binding activity. Western blotting was conducted to analyze NF-κB p65 in the nucleus and its acetylation. RESULTS: JQ1 dose-dependently improved the histopathological changes in the lung tissues and decreased the mean linear intercept (MLI), destructive index and inflammatory score of the mice with COPD. The mice with COPD showed increased levels of MMP-2, MMP-9, IFN-γ, IL-17, IL-1β, IL-6 and TNF-α with decreased IL-10 level; these changes were reversed by JQ1 in a dose-dependent manner. In addition, JQ1 reduced the MDA level and increased the SOD, HO-1 and T-AOC levels in mice with COPD, with suppression of NF-κB p65 expression in the nucleus, NF-κB/p65 (Lys310) acetylation and NF-κB p65/DNA binding activity in the lung tissues. CONCLUSION: The BRD4 inhibitor JQ1 can downregulate MMP-2 and MMP-9 expression, reduce inflammatory responses, and alleviate oxidative stress in mice with COPD, and this mechanism might be related to the inhibition of NF-κB.
OBJECTIVE: To examine the effect of the BRD4 inhibitor JQ1 on mice with chronic obstructive pulmonary disease (COPD) via NF-κB. METHODS:COPD models constructed by exposure to cigarette smoke and intratracheal instillation of lipopolysaccharides (LPS) in mice were treated with JQ1 (15, 25 or 50 mg/kg). HE staining was performed to observe histopathological changes in the lung tissues. Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of IL-10, IFN-γ, IL-17, IL-1β, IL-6, TNF-α, MMP-2, MMP-9, MDA, SOD, T-AOC and HO-1, and gelatin zymography assays were used to examine MMP-2 and MMP-9 activity. A TransAMTM NF-κB p65 detection kit was used to test NF-κB p65/DNA binding activity. Western blotting was conducted to analyze NF-κB p65 in the nucleus and its acetylation. RESULTS: JQ1 dose-dependently improved the histopathological changes in the lung tissues and decreased the mean linear intercept (MLI), destructive index and inflammatory score of the mice with COPD. The mice with COPD showed increased levels of MMP-2, MMP-9, IFN-γ, IL-17, IL-1β, IL-6 and TNF-α with decreased IL-10 level; these changes were reversed by JQ1 in a dose-dependent manner. In addition, JQ1 reduced the MDA level and increased the SOD, HO-1 and T-AOC levels in mice with COPD, with suppression of NF-κB p65 expression in the nucleus, NF-κB/p65 (Lys310) acetylation and NF-κB p65/DNA binding activity in the lung tissues. CONCLUSION: The BRD4 inhibitor JQ1 can downregulate MMP-2 and MMP-9 expression, reduce inflammatory responses, and alleviate oxidative stress in mice with COPD, and this mechanism might be related to the inhibition of NF-κB.
Authors: A Alzoubi; R Ghazwi; K Alzoubi; M Alqudah; K Kheirallah; O Khabour; M Allouh Journal: Folia Morphol (Warsz) Date: 2018-01-03 Impact factor: 1.183
Authors: Raquel Annoni; Tatiana Lanças; Ryan Yukimatsu Tanigawa; Marcus de Medeiros Matsushita; Sandra de Morais Fernezlian; Andreina Bruno; Luiz Fernando Ferraz da Silva; Peter J Roughley; Salvatore Battaglia; Marisa Dolhnikoff; Pieter S Hiemstra; Peter J Sterk; Klaus F Rabe; Thais Mauad Journal: Eur Respir J Date: 2012-04-10 Impact factor: 16.671
Authors: Daniela A B Cervilha; Juliana T Ito; Juliana D Lourenço; Clarice R Olivo; Beatriz M Saraiva-Romanholo; Rildo A Volpini; Manoel C Oliveira-Junior; Thais Mauad; Milton A Martins; Iolanda F L C Tibério; Rodolfo P Vieira; Fernanda D T Q S Lopes Journal: Sci Rep Date: 2019-02-13 Impact factor: 4.379
Authors: L L da Motta; I Ledaki; K Purshouse; S Haider; M A De Bastiani; D Baban; M Morotti; G Steers; S Wigfield; E Bridges; J-L Li; S Knapp; D Ebner; F Klamt; A L Harris; A McIntyre Journal: Oncogene Date: 2016-06-13 Impact factor: 9.867